Bli medlem
Bli medlem

Du är här


CellaVision AB: Bulletin from the Annual General Meeting of CellaVision AB (publ) held on May 4, 2016

Press release May 6, 2016

Bulletin from the Annual General Meeting of CellaVision AB (publ) held on May
4, 2016

CellaVision AB (publ) held its Annual General Meeting today, 4 May 2016, in
Lund. The meeting resolved upon the following:

* Payment of dividend in the amount of SEK 1,50 per share with 9 May 2016 as
record date, meaning that payment is expected to be made on 12 May 2015.
* Discharge from liability for the members of the Board of Directors and the
President and CEO.
* Re-election of Anna Malm Bernsten, Christer Fåhraeus, Åsa Hedin, Roger
Johanson, Torbjörn Kronander and Niklas Prager as members of the Board of
Directors. Election of Sören Mellstig as a new member of the Board of
Directors. Re-election of the auditor.
* Resolution on remuneration for the members of the Board of Directors and
the auditor.
* Resolution on an incentive program for the company management. Those
eligible are the CEO and members of the executive management.

More detailed information concerning the resolutions passed at the general
meeting of shareholders is available in Swedish only.

CEO Zlatko Rihter's address to the meeting is available at the Investor pages
at CellaVision's website

For more information, please contact:

Zlatko Rihter, CEO, CellaVision AB.

Phone: +46 733 62 11 06,

About CellaVision

CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other
body fluids in health care services. The products rationalize manual
laboratory work, and secure and support effective workflows and skills
development within and between hospitals. The company has leading-edge
expertise in image analysis, artificial intelligence and automated
microscopy. Sales are via global partners with support from the mother
company in Lund and by the market support organizations in the US, Canada,
China and Japan. In 2015 sales were SEK 239 million and sales continue to
increase, with a growth target of at least 15 % per year over an economic
cycle. CellaVision's registered office is in Lund, Sweden. The share is
listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at


The information in this press release comprises such information as
CellaVision AB (publ) is required to publish in accordance with the
Securities Market Act and/or the Financial Instruments Trading Act. This
information was released for public disclosure on May 6, 2016 at 08:20 CET.

Press release as pdf


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.